WHO guidelines for the clinical management of filovirus disease: executive summary

Overview

This executive summary presents the WHO guidelines for the clinical management of filovirus disease, encompassing infections caused by Bundibugyo, Ebola, Marburg, Sudan and Taï Forest viruses. The guidelines expand previous WHO clinical guidance focused on Ebola virus disease and provide evidence-based recommendations developed through systematic reviews and the GRADE framework. The document outlines the rationale, scope and methods used in guideline development, including multidisciplinary expert consultation, evidence appraisal and consideration of implementation factors such as feasibility, equity and resource use.

The guidelines address key clinical interventions to improve outcomes for patients with suspected or confirmed filovirus disease. Recommendations cover systematic clinical and laboratory monitoring, oral and intravenous fluid management, assessment and treatment of shock, use of vasopressors, central venous access, antimicrobial therapy, management of haemorrhage and postpartum haemorrhage, and structured follow-up for survivors. Emphasis is placed on high-quality supportive care, individualized clinical decision-making and integration with infection prevention and control measures. The document highlights the importance of strengthening clinical capacity and applying person-centred approaches to reduce mortality, improve recovery and support long-term health outcomes following filovirus disease.